Zai Lab Ltd (ZLAB): Market Cap to Revenue Ratio

Symbol and logo of brand Zai Lab Ltd (ZLAB)

Zai Lab Limited (ZLAB) builds its defensive moat through exclusive licenses for Western biologics and deep regulatory expertise. The production cycle relies on a combination of proprietary plants in Suzhou and contract manufacturing capacities. Revenue is generated by introducing innovative drugs to the Chinese market. The current price-to-sales ratio on this chart illustrates the valuation trend, where 6.60 represents the current level of the metric.

Zai Lab Corp (ZLAB) Market Cap to Revenue: for the period 07/04/2022 - 11/13/2026

Analytical breakdowns for Zai Lab Ltd. (ZLAB)

- price and consensus price forecast:
Market Chart zailaboratory.com|ZLAB - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Zai Lab Ltd.|ZLAB - Enterprise Value
- business book valuation details:
Book Value of One Share Zai Lab|ZLAB - Company Net Assets|Market Capitalization to Net Assets zailaboratory.com|ZLAB - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Zai Lab Limited|ZLAB - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Zai Lab Corp|ZLAB - Company Total Debt|Debt to Net Assets Ratio Zai Lab Ltd.|ZLAB - Company Long-Term Debt|Company Short-Term Debt Zai Lab|Quick Ratio zailaboratory.com
- earnings and market multiples details:
ZLAB - Net Profit|Expected Profit Zai Lab Limited|ZLAB - Price to Earnings Ratio|Future Price to Earnings Multiple Zai Lab Ltd|ZLAB - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Zai Lab Ltd.|ZLAB - Operating profit EBITDA|Net earnings per share for the last four quarters Zai Lab|ZLAB - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months zailaboratory.com|ZLAB - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Zai Lab Limited
- sales revenue and business income indicators:
ZLAB - Company Sales|Company Projected Revenue Volume zailaboratory.com|ZLAB - P/S Multiple|Market Cap to Future Revenue Ratio Zai Lab Ltd.
Summary company analytics:zailaboratory.com, ZLAB
Signature product of Zai Lab Limited

Optimizing drug distribution in Asia directly impacts the revenue of Zai Lab Limited (ZLAB), which serves as the denominator in the P/S ratio calculation. This metric compares the business's market value with its actual sales volumes, allowing the price-to-sales multiple history to determine whether the low share price results from a fundamental decline in commercial activity and the risk of capital freezing.

Competitors of Zai Lab Limited

Price-to-Revenue Coefficient lilly.com|Price-to-Revenue Ratio AbbVie ABBV|AZN: Market Cap to Revenue Ratio|Novartis Inc. - P/S Multiple|Price-to-Revenue Multiple MSD (MRK)|NVO (Novo Nordisk A/S) - Market Cap to Revenue|Price-to-Sales Ratio AMGN (amgen.com)|PFE (Pfizer) - P/S Multiple|P/S Multiple Sanofi SA|P/S Multiple BMY|Price-to-Revenue Coefficient gsk.com|Takeda Pharmaceutical - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TEVA|RDY - Price-to-Revenue Ratio|VTRS: Price-to-Revenue Ratio|ROIV: P/S Multiple|Bausch Health Corp (BHC) - P/S Multiple|COSM (Cosmos Health Inc.) - P/S Multiple